As shown in Figure 3A, ovarian cancer patients with higher levels of UBE2C expression tended to have shorter OS (log-rank p = 0.00038), lower progression-free survival (PFS; log-rank p = 0.04), and worse post-progression survival (PPS; log-rank p = 0.0017). Here, UBE2C is linked to ovarian carcinoma.